Stereotactic Radiation Therapy (SBRT/SRS) — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p>Stereotactic radiation therapy (SRT) is a highly precise, image-guided form of radiation treatment that delivers very high doses of ionising radiation to a precisely defined tumour target in one (radiosurgery) or a small number of treatment sessions (typically 3–5), while minimising radiation exposure to the surrounding healthy tissue. The word <em>stereotactic</em> derives from the Greek <em>stereos</em> (solid, three-dimensional) and Latin <em>tactus</em> (touch), reflecting the three-dimensional coordinate system used to locate the treatment target with sub-millimetre accuracy relative to external reference points or implanted fiducial markers.</p><p>When applied to brain tumours and intracranial targets, the technique is called <strong>stereotactic radiosurgery (SRS)</strong> — a term coined by neurosurgeon Lars Leksell in the 1950s to describe the concept of delivering a single-fraction, high-dose radiation treatment to an intracranial target as precisely as a surgeon's scalpel, without a physical incision. When applied to targets in the body (lung, liver, spine, adrenal glands, kidney, prostate), the technique is called <strong>stereotactic body radiation therapy (SBRT)</strong> or, in European and Australian convention, stereotactic ablative radiotherapy (<strong>SABR</strong>).</p><p>The fundamental radiobiological principle distinguishing SBRT/SRS from conventional fractionated radiotherapy is the delivery of a ablative dose per fraction (typically 6–24 Gy per fraction, compared with 1.8–2 Gy per fraction in conventional RT). Such high doses exploit a different biological mechanism — direct vascular injury to the tumour's blood supply, causing irreversible ischaemic tumour ablation — in addition to the conventional DNA double-strand break mechanism that underpins lower-dose fractionated radiation.</p><p>Key technology platforms include: the <strong>Gamma Knife</strong> (Elekta), which uses 192 cobalt-60 sources focused on a single point; <strong>CyberKnife</strong> (Accuray), a robotic linear accelerator that moves around the patient on a robotic arm and does not require a rigid head frame; and <strong>LINAC-based systems</strong> (Varian TrueBeam, Brainlab), which use volumetric modulated arc therapy (VMAT) or dynamic conformal arcs to deliver stereotactic doses on conventional radiotherapy machines with added precision hardware. These platforms differ in their geometry, dose delivery speed, imaging capabilities, and optimal clinical applications.</p>

<p>Stereotactic radiation therapy has transformed the management of a wide spectrum of intracranial and extracranial conditions, becoming the preferred non-surgical treatment for many tumours and vascular abnormalities.</p><h4>Intracranial Indications</h4><p><strong>Brain Metastases:</strong> SRS is the standard treatment for 1–4 brain metastases (and increasingly for 5–10 lesions, per randomised trial evidence from JCOG0504 and other studies), providing excellent local control rates of 85–95% at 1 year for lesions up to 3 cm, while avoiding the cognitive toxicity of whole-brain radiotherapy (WBRT). SRS is used both definitively and as an adjunct to surgical resection (post-operative SRS to the resection cavity).</p><p><strong>Arteriovenous Malformations (AVMs):</strong> Gamma Knife SRS is a primary treatment option for brain AVMs not amenable to microsurgical resection or embolisation, achieving obliteration in 70–80% of lesions over 2–3 years. The radiobiological mechanism involves progressive endothelial proliferation within the AVM nidus, ultimately thrombosing the abnormal vessels.</p><p><strong>Benign Intracranial Tumours:</strong> Meningiomas (WHO Grade I), vestibular schwannomas (acoustic neuromas), and pituitary adenomas are highly suitable for SRS/SRT, achieving tumour growth control in 90–95% at 5 years while preserving cranial nerve function. SRS is the preferred treatment for small-to-medium schwannomas in patients seeking hearing preservation.</p><p><strong>Trigeminal Neuralgia:</strong> Gamma Knife SRS targets the trigeminal nerve root entry zone with 70–90 Gy in a single fraction, achieving pain relief in 70–85% of patients with this debilitating facial pain condition. Response typically develops over 1–3 months post-treatment.</p><h4>Extracranial (Body) Indications — SBRT</h4><p><strong>Early-Stage Non-Small Cell Lung Cancer (NSCLC):</strong> SBRT delivers 54–60 Gy in 3–5 fractions to medically inoperable peripheral stage I/IIA NSCLC, achieving local control rates of 85–95% comparable to surgery (lobectomy), without general anaesthesia or surgical morbidity. SBRT is now the standard of care for inoperable peripheral early lung cancer (ASTRO/ESTRO guidelines).</p><p><strong>Liver Tumours:</strong> SBRT for hepatocellular carcinoma (HCC), cholangiocarcinoma, and liver metastases delivers 25–60 Gy in 3–6 fractions, achieving local control rates of 70–90% for lesions up to 6 cm, with acceptable liver toxicity when residual liver volume is preserved.</p><p><strong>Spine Tumours:</strong> Stereotactic body radiosurgery (SBRS) to spinal metastases achieves long-term local control of 80–90% for treatment-naive and radioresistant histologies (renal cell carcinoma, melanoma, sarcoma), with acceptable rates of vertebral body fracture and radiation myelopathy using modern planning constraints.</p><p><strong>Prostate Cancer:</strong> SBRT for localised prostate cancer (5-fraction treatment delivering 35–40 Gy) is an established standard of care per ASTRO guidelines, offering equivalent tumour control to conventional 8-week fractionated RT or brachytherapy in 1 week of treatment.</p>

<p>Patient eligibility for stereotactic radiation therapy is determined through a multi-disciplinary tumour board discussion that considers tumour characteristics, patient performance status, prior treatment history, and technical factors related to target delineation and normal tissue sparing.</p><h4>Tumour Size and Number</h4><p>Size is the most critical eligibility determinant. SRS for brain metastases is most effective and safest for lesions up to 3 cm in maximum diameter; lesions of 3–4 cm can be treated but with increased risk of radiation necrosis. For SBRT to the body, tumour size thresholds depend on the site: peripheral lung tumours up to 5 cm for 3-fraction SBRT; centrally located lung tumours (<2 cm from the bronchial tree) require extended fractionation (8 fractions or more) to avoid bronchial toxicity; liver lesions up to 6 cm in patients with adequate liver reserve; and spine lesions provided there is adequate separation from the spinal cord.</p><p>For brain metastases, the number of lesions has historically been limited to 1–4 for SRS to avoid cumulative dose to the brain. Growing randomised trial evidence supports SRS for 5–10 lesions in selected patients, and some centres treat even more with close monitoring.</p><h4>Performance Status</h4><p>Patients must have a sufficiently good performance status to benefit from treatment and to tolerate the positioning and immobilisation required. For SBRT to body sites, patients must be able to lie still for 30–60 minutes per session and to maintain their breath as instructed (for respiratory gating). ECOG performance status 0–2 is the general eligibility threshold, though SRS to the brain (a short, non-invasive procedure) can be offered to patients with poorer status who have symptomatic brain lesions.</p><h4>Prior Radiation History</h4><p>Prior radiotherapy to the same region (re-irradiation) is technically feasible with SRS/SBRT when sufficient time has elapsed and cumulative dose constraints can be respected. Re-irradiation SRS for recurrent brain metastases after prior WBRT or prior SRS is an active and growing clinical field. Spinal re-irradiation with stereotactic body radiosurgery requires particularly careful dosimetric planning to avoid exceeding spinal cord tolerance.</p><h4>Contraindications</h4><p>Absolute or relative contraindications include: tumour abutting a critical serial structure (optic nerve, brainstem, spinal cord) where dose constraints cannot be respected; uncontrolled systemic disease making life expectancy less than 3–6 months (limiting benefit from a treatment with delayed radiobiological effect); leptomeningeal carcinomatosis (diffuse spread); active infection or severe coagulopathy precluding any procedural intervention; and inability to maintain treatment position due to claustrophobia, severe pain, or cognitive impairment.</p><p>Patients with pacemakers or implantable cardiac devices can usually be treated safely, but device proximity to the beam path and the potential for radiation-induced device malfunction must be evaluated by the radiation oncology physics team in conjunction with cardiology.</p>

<p>Multiple technology platforms deliver stereotactic radiation therapy, and the optimal choice depends on the treatment target (brain vs body), tumour size, institutional availability, and clinical factors.</p><h4>Gamma Knife (Leksell Gamma Knife — Elekta)</h4><p>The Gamma Knife is the gold-standard device for intracranial SRS, using 192 cobalt-60 radioactive sources arranged in a hemispherical helmet that focus beams precisely on a central isocenter. The Gamma Knife Icon model enables frameless SRS using stereotactic cone-beam CT image guidance and a thermal plastic mask, expanding its application to fractionated stereotactic radiotherapy (FSRT) as well as single-fraction SRS. Sub-millimetre geometric accuracy and decades of clinical experience make it the benchmark for intracranial SRS. It is not designed for body (extracranial) treatments.</p><h4>CyberKnife (Accuray)</h4><p>The CyberKnife uses a compact linear accelerator mounted on a six-degree-of-freedom robotic arm that can point the beam from hundreds of different angles around the patient. Real-time image guidance using orthogonal X-ray imaging tracks the target position and robot position continuously, correcting for patient motion between and during treatment. CyberKnife is particularly well-suited for non-isocentric (irregularly shaped) intracranial targets, spinal tumours with real-time tracking, and body SBRT where respiratory motion management is important (lung, liver). No head frame is required for intracranial treatment — fully frameless. Treatment sessions are longer than Gamma Knife but extremely precise.</p><h4>LINAC-Based Stereotactic Systems (Varian TrueBeam, Brainlab Elements, Elekta VERSA HD)</h4><p>Modern linear accelerators equipped with high-definition multi-leaf collimators (HD-MLCs), 6-degree-of-freedom treatment couches, and onboard cone-beam CT imaging can deliver SRS and SBRT with precision approaching that of dedicated SRS platforms. LINAC-based SRS using volumetric modulated arc therapy (VMAT) is faster than Gamma Knife for most lesions (<15 minutes for small single metastases) and allows treatment of brain and body targets on the same machine. This versatility, combined with the wide availability of modern LINACs in cancer centres globally, makes LINAC-based stereotactic RT the most widely delivered form of SRS/SBRT worldwide.</p><h4>Single-Fraction SRS vs Multi-Fraction SBRT</h4><p>Single-fraction SRS (typically 15–24 Gy for brain metastases) offers the radiobiological advantage of maximum ablative effect in a single visit and a precise binary response (cell kill or not), minimising repopulation. However, the risk of radiation necrosis (late brain injury) increases substantially with single-fraction doses above 18–20 Gy for lesions greater than 2 cm. Multi-fraction SBRT (e.g., 3 × 9 Gy = 27 Gy, or 5 × 7 Gy = 35 Gy for brain metastases) reduces the risk of late necrosis while maintaining high biologically effective doses for tumour kill, and is preferred for larger lesions near critical structures and for body sites.</p><h4>Respiratory Motion Management for SBRT</h4><p>Body targets (lung, liver) move with respiration, requiring specific motion management strategies: breath-hold (abdominal compression or active breath hold), respiratory gating (treating only during a specific phase of the breathing cycle), or real-time target tracking (CyberKnife Synchrony). Proper motion management is essential to ensure the delivered dose matches the planned dose and to avoid margining errors that could increase toxicity or miss the target.</p>

<p>Stereotactic radiation therapy offers a unique combination of clinical efficacy and patient-friendly delivery that makes it one of the most valuable technological advances in oncology over the past 30 years.</p><h4>High Local Control Without Surgery</h4><p>SRS and SBRT achieve local control rates comparable to surgery for carefully selected targets: 85–95% 1-year local control for brain metastases treated with SRS, matching microsurgical resection; 85–95% 3-year local control for peripheral early-stage NSCLC with SBRT, equivalent to lobectomy in multiple population-based retrospective analyses and prospective single-arm trials. The SPACE and STARS trials (though prematurely closed due to accrual issues) and extensive retrospective data support SBRT as a surgical equivalent for inoperable and operable patients who prefer a non-surgical option.</p><h4>Non-Invasive Outpatient Treatment</h4><p>SRS and SBRT are almost entirely non-invasive. No incisions, no general anaesthesia (for adults), no blood loss, and no surgical recovery period are required. Treatment sessions for brain SRS take 20–60 minutes, after which the patient walks out of the treatment suite and is typically able to return to normal activities the following day. Body SBRT sessions take 30–90 minutes depending on site complexity. The entire SBRT course for lung or prostate cancer is completed in 1 week (5 sessions) compared with 7–8 weeks of conventional daily radiotherapy.</p><h4>Precision Sparing of Healthy Tissue</h4><p>The steep dose gradient produced by stereotactic delivery — dose falling by 50% within 2–5 mm of the target edge — spares immediately adjacent healthy brain, lung, or liver tissue from the high ablative doses delivered to the tumour. This precision is critical near eloquent brain regions (motor cortex, Broca's area), optic pathways, brainstem, and in the lung where preserving functional alveolar volume determines post-treatment pulmonary reserve.</p><h4>Preservation of Neurocognitive Function</h4><p>SRS for brain metastases preserves neurocognitive function significantly better than whole-brain radiotherapy (WBRT). The landmark NCCTG N0574 trial (Brown et al., JAMA 2016) demonstrated that SRS alone — compared with SRS plus WBRT — produced substantially better cognitive function at 3 months while maintaining comparable survival, cementing SRS as the standard approach for limited (1–4) brain metastases.</p><h4>Applicability to Medically Inoperable Patients</h4><p>SBRT provides an effective treatment option for patients with early lung, liver, or prostate cancer who cannot tolerate surgery due to cardiovascular co-morbidities, poor pulmonary reserve, prior abdominal surgery, or advanced age. For these patients, SBRT can be truly life-extending or curative without the procedural mortality risk of surgery.</p>

<p>Although substantially gentler than open surgery, stereotactic radiation therapy carries treatment-specific side effects and risks that depend on the target location, dose delivered, fractionation scheme, and proximity to critical structures.</p><h4>Radiation Necrosis (Brain SRS)</h4><p>Radiation necrosis — an area of late radiation injury in normal brain tissue adjacent to the treated target — is the most clinically significant toxicity of intracranial SRS. It typically presents 6–18 months post-treatment with imaging changes (ring-enhancing lesion on MRI, increased FDG uptake on PET) that can be difficult to distinguish from tumour recurrence. Symptomatic radiation necrosis occurs in approximately 5–10% of single-fraction SRS treatments and may require: high-dose corticosteroids (dexamethasone) for weeks to months; bevacizumab (anti-VEGF monoclonal antibody), which is highly effective in resolving radiation necrosis in 70–80% of cases; laser interstitial thermal therapy (LITT, a minimally invasive surgical option); or rarely, conventional surgical excision.</p><h4>Acute Side Effects</h4><p>In the first 24–72 hours after SRS, patients may experience: fatigue; headache (particularly with intracranial SRS from transient cerebral oedema); nausea and vomiting; skin erythema at the beam entry points (mild in most cases); and pin-site discomfort if a stereotactic head frame was applied. These acute effects are usually mild, self-limiting, and managed with simple analgesics and anti-emetics.</p><h4>Site-Specific SBRT Toxicities</h4><p><strong>Lung SBRT:</strong> Fatigue and mild radiation pneumonitis (cough, low-grade fever) in 5–15% of patients; severe pneumonitis requiring systemic corticosteroids in 1–5%. Central lung tumours treated at high dose per fraction carry risk of airway fistula, haemoptysis, and brachial plexus injury.</p><p><strong>Liver SBRT:</strong> Radiation-induced liver disease (RILD) — a form of veno-occlusive hepatopathy — in 5–10% of cases, most commonly in patients with pre-existing cirrhosis or Child-Pugh B liver function. Rigorous dosimetric constraints on mean liver dose are essential to prevention.</p><p><strong>Spinal SBRT:</strong> Vertebral body fracture in 5–15% of treated vertebrae (risk increased by baseline fracture, lytic lesion, high dose per fraction, and tumour involvement >40% of vertebral body); radiation myelopathy is rare (<1%) with modern dose constraints.</p><p><strong>Prostate SBRT:</strong> Urinary frequency, dysuria, and rectal urgency/bleeding during treatment (Grade 2 toxicity in 20–30% of patients; Grade 3 in less than 3%). Late toxicity rates are comparable to conventional RT.</p>

<p>Recovery after SRS and SBRT is generally rapid, and follow-up is centred on assessing treatment response, monitoring for treatment-related side effects, and planning further systemic therapy if needed.</p><h4>Immediate Post-Treatment Period</h4><p>After brain SRS, most patients experience mild fatigue and possibly a headache or nausea on the day of treatment. A short course of dexamethasone (2–4 mg daily for 3–5 days) is often prescribed to reduce peri-tumoral oedema. Anti-epileptic medications are prescribed if the patient had pre-existing seizures. Patients can usually return to normal activities — including light work — within 24–48 hours of treatment. After SBRT to body sites, mild fatigue typically lasts 1–2 weeks; other symptoms depend on the treatment site.</p><h4>Imaging Surveillance</h4><p>For brain metastases treated with SRS: MRI brain with gadolinium contrast is performed at 6–8 weeks post-treatment (to establish a new baseline), then every 2–3 months for the first year, and every 3–6 months thereafter. The treated lesion typically shows central necrosis and peripheral contrast enhancement — changes that must be distinguished from tumour recurrence, often requiring advanced imaging (MR perfusion, MR spectroscopy, FET-PET, or LITT biopsy in ambiguous cases). For lung SBRT: CT thorax at 3 months, 6 months, 12 months, and annually. Fibrotic scar at the treated site is expected and should not be mistaken for recurrence. For liver SBRT: contrast-enhanced CT or MRI at 3 and 6 months.</p><h4>Assessment for Salvage Treatment</h4><p>Local recurrence after SRS or SBRT — confirmed by biopsy or characteristic imaging progression — may be managed with: repeat SRS (if the cumulative dose to adjacent brain or spinal cord permits); surgical resection (craniotomy for large brain recurrences with mass effect); systemic therapy modification (changing to a more CNS-penetrant agent for brain metastases); or in patients with multiple brain metastases, salvage WBRT as a last resort.</p><h4>Systemic Therapy Coordination</h4><p>SRS and SBRT are increasingly delivered in combination with immunotherapy (checkpoint inhibitors — pembrolizumab, nivolumab, atezolizumab) and targeted therapy. The combination of SRS with immunotherapy shows early signals of an abscopal effect — immune-mediated tumour regression at non-irradiated systemic sites. Timing of systemic therapy around SBRT is important: some agents (gemcitabine, certain TKIs) increase radiation toxicity and are typically held for 1–2 weeks around SBRT.</p>

<p>The cost of stereotactic radiation therapy varies substantially based on the technology platform, number of fractions, complexity of treatment planning, country, and hospital type. Medical travel — particularly to India, Thailand, or Turkey — can reduce costs by 60–80% compared with high-income countries.</p><h4>Cost by Country</h4><p>In the <strong>United States</strong>, SRS for a single brain metastasis costs USD 20,000–40,000, and a full course of lung SBRT (5 fractions) costs USD 25,000–60,000. Prostate SBRT costs USD 30,000–50,000. These figures include simulation CT, treatment planning, physics quality assurance, treatment delivery, and 3-month follow-up.</p><p>In <strong>India</strong> at major cancer centres (Tata Memorial, AIIMS, Apollo Cancer Centres, Fortis Cancer Institute, HCG Hospitals, Manipal Hospitals), Gamma Knife SRS costs approximately USD 3,000–6,000 per session; CyberKnife SRS/SBRT costs USD 4,000–10,000 for a full course; and LINAC-based SBRT costs USD 3,500–8,000 for a complete course including simulation and planning. <strong>Thailand</strong> (Bumrungrad Cancer Centre): USD 8,000–15,000. <strong>Turkey</strong> (Acibadem, Medical Park): USD 6,000–12,000. <strong>Malaysia</strong> (Pantai, Gleneagles): USD 7,000–14,000.</p><h4>Key Cost Drivers</h4><p>(1) <strong>Number of fractions:</strong> Single-fraction SRS is typically less expensive than 5-fraction SBRT (fewer patient visits, less physics work). However, highly complex single-fraction SRS (multiple simultaneous metastases, very small targets requiring intense physics QA) can be more expensive. (2) <strong>Technology platform:</strong> Gamma Knife and CyberKnife have high capital costs passed to patients; LINAC-based SRS at high-volume centres may be less expensive. (3) <strong>Treatment planning complexity:</strong> Multi-target plans, re-irradiation cases, and cases requiring special dosimetric consideration (brainstem or optic nerve proximity) require more physics time and expertise. (4) <strong>Image guidance and simulation:</strong> MRI-guided treatment planning with fiducial placement (in prostate SBRT) and 4D-CT for respiratory motion characterisation add cost.</p><h4>Medical Travel Considerations</h4><p>For medical travellers, SRS or SBRT is logistically convenient because the treatment course is short (1–5 days of treatment) and follow-up can be managed remotely or at a local hospital using radiology image sharing. Patients should allow 1–2 weeks in the destination country for planning imaging, simulation, and treatment. Planning scans (CT simulation, MRI) can sometimes be performed at home and sent electronically, with final verification scans performed on arrival. Ensure the treating centre provides a comprehensive treatment summary and all DICOM planning files for continuity of follow-up care at home.</p>

<p>Depending on the specific condition, tumour size, location, and patient factors, several alternatives to SRS and SBRT should be considered in the treatment planning discussion.</p><h4>Surgical Resection</h4><p>For brain metastases causing significant mass effect or oedema, producing neurological deficits, or where histological confirmation is needed, surgical resection (craniotomy) provides immediate mass reduction and histological diagnosis. Randomised trials (Patchell et al., NEJM 1990) established that surgery plus WBRT improved survival over WBRT alone for single brain metastases. Modern practice uses post-operative SRS to the resection cavity (a combination superior to either surgery alone or SRS alone for larger lesions). For early-stage lung cancer, video-assisted thoracoscopic surgery (VATS) lobectomy remains the standard of care for operable patients in good cardiorespiratory health, with 5-year survival rates of 70–80% for stage I NSCLC — slightly better than SBRT in the head-to-head STARS and ROSEL trial individual patient data meta-analysis.</p><h4>Conventional Fractionated Radiotherapy (IMRT/VMAT)</h4><p>For larger tumours, targets adjacent to critical serial structures (optic nerve, brainstem), or conditions where the fractionation advantage (better tissue repair between fractions) is important, conventional fractionated RT over 5–7 weeks delivers the total dose in 25–35 smaller daily fractions. Intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) achieve highly conformal dose distributions comparable to SRS/SBRT in terms of target coverage, though with lower dose per fraction and thus a different biological mechanism and toxicity profile.</p><h4>Proton Beam Therapy</h4><p>Proton therapy offers a unique physical dose distribution: protons deposit most of their dose at the Bragg peak (the end of their range), with minimal exit dose. This can substantially reduce dose to normal tissues distal to the target — particularly valuable for tumours in or near the brainstem, spinal cord, optic nerve, or heart. Proton stereotactic radiosurgery and proton SBRT are available at proton centres worldwide, though at higher cost than photon SRS/SBRT.</p><h4>Whole-Brain Radiotherapy (WBRT)</h4><p>For patients with extensive brain metastases (>10 lesions), leptomeningeal involvement, or very poor performance status where SRS is not feasible, WBRT (30 Gy in 10 fractions) provides palliative symptom control. Hippocampal-avoiding WBRT with memantine reduces but does not eliminate the neurocognitive toxicity of WBRT. WBRT is now generally reserved for patients not suitable for or who have failed SRS.</p><h4>Interventional Ablation Techniques</h4><p>For liver and kidney tumours, image-guided thermal ablation techniques — radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation — deliver local tumour destruction via percutaneous needle insertion under CT or ultrasound guidance. For small (<3 cm) liver tumours, RFA achieves local control rates comparable to SBRT and may be preferred where the tumour is accessible and not adjacent to major bile ducts or hepatic veins. These techniques are minimally invasive alternatives for patients in whom SBRT is not available or technically feasible.</p>